RCUS News and Press, Arcus Biosciences Inc. From 01/30/24

2024-01-30 08:39:01 ET Iterum Therapeutics  ( ITRM ) +61% Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections. Kura Oncology  ( KURA ) +16% Reports Positive Preliminary Ziftomen...

2024-01-29 18:06:10 ET More on Gilead Sciences, Arcus Biosciences, etc. Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold ...

– Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program – – Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33% – – Ame...

2024-01-24 09:10:00 ET January 24, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of new stocks to watch in Biotech, Defense, Energy and Homebuilder sectors. Today's stocks have been added to Invest...

2024-01-22 05:00:00 ET Summary After a correction from August through October, the market has been on a tear. Technology had a very good week, especially among the Magnificent 7 mega-cap stocks. The S&P Top 7 stocks continue to dominate the market, but that dominance is sl...

2024-01-17 07:52:49 ET More on Gilead, Arcus Biosciences, etc. Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Gile...

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A 37% reduction in risk of death and a 5.9-month improvement in median overall survival was ...

2024-01-11 00:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...

2023-12-24 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...